Topical cocaine can treat ABMD

Article

Cocaine-assisted epithelial debridement is a simple and inexpensive treatment method for symptomatic anterior basement membrane dystrophy (ABMD) patients, reveals the latest study in the journal Cornea.

Cocaine-assisted epithelial debridement is a simple and inexpensive treatment method for symptomatic anterior basement membrane dystrophy (ABMD) patients, reveals the latest study in the journal Cornea.

Dr Rony R. Sayegh et al., Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA, conducted a retrospective chart review on 33 eyes of 27 symptomatic patients with ABMD who were treated with 4% topical cocaine followed by epithelial debridement.

The main outcome measures included preoperative and postoperative best-corrected visual acuities (BCVA), topography, subjective symptoms, complications and evidence of disease recurrence.

Recurrent erosion symptoms were present in 17 eyes of 14 patients (group 1) and 16 eyes of 13 patients (group 2) experienced reduced visual acuity from irregular astigmatism.

Group 1 presented with one patient who experienced symptomatic recurrence of the corneal erosion. In group 2 one patient experienced significant postoperative corneal haze. BCVA in group 1 improved from an average of 20/45 preoperatively to 20/38 at the last follow-up visit and 20/63 to 20/32 in group 2.

The treatment is ideal for ABMD patients who experience recurrent corneal erosions or irregular astigmatism, causing decreased visual acuity.

Please click here to read the study abstract.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.